Latest news
What’s the difference between IBS and IBD?
These GI conditions sound similar, and they also share some symptoms. But IBS and IBD are distinct disorders—especially when it comes to treatment and the risk of complications.
How robots are helping personalize knee replacement surgery
For Arthritis Awareness Month, learn the latest about this common procedure and how Johnson & Johnson MedTech is innovating to improve patient outcomes.
More from Johnson & Johnson
“I couldn’t speak, walk or sit.” Inside a rare autoimmune disease that attacks the muscles
Elisa Glass was diagnosed with dermatomyositis, which causes severe muscle weakness throughout the body. For Myositis Awareness Month, she shares her story.
5 things we now know about bladder cancer
Paradigm-shifting new therapies are helping people with the disease lead longer, more comfortable lives. For Bladder Cancer Awareness Month, learn how Johnson & Johnson is helping to change the treatment landscape.
What is a gene mutation?
Experts aren’t sure why, but sometimes changes in DNA can trigger cancer to grow and spread. For DNA Day learn all about gene mutations—and Johnson & Johnson’s work developing new therapies to target these specific types of cancer.
Reconnecting the meaning of these two simple words: Health&Care
Johnson & Johnson is restoring the true meaning of healthcare by developing advanced treatments and smarter and less invasive solutions for today’s most complex diseases.
Building climate-resilient health clinics
When Mother Nature strikes—think triple-digit heatwaves, wildfires, hurricanes—vulnerable populations are at risk of missing out on much-needed healthcare. For Earth Day, learn how Johnson & Johnson is helping community clinics protect patients.
What is IL-23?
This pro-inflammatory protein is the target of potential Johnson & Johnson medications that could help treat autoimmune conditions such as psoriasis, inflammatory bowel disease and rheumatoid arthritis.
Press releases
Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment
Acquisition advances Johnson & Johnson’s leading Dermatology portfolio with opportunity to address significant unmet need in atopic dermatitis (AD) Includes bispecific antibodies targeting proven disease pathways and offers the potential to provide best-in-disease therapeutics for people with moderate to severe AD and asthma These pipeline additions demonstrate the Company’s strategic approach to build a portfolio of differentiated and complementary bispecifics to address multiple disease-driving pathways
Biosense Webster Launches New Version of CARTO™ 3 Electro-Anatomical Mapping System
New CARTO™ 3 System Version 8 software introduces machine learning capabilities Increases efficiency, reproducibility, and accuracy1 in the electro-anatomical maps electrophysiologists use in catheter ablation procedures
TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non–muscle-invasive bladder cancer, respectively
Updated results reinforce the potential of TAR-210 to transform treatment of non–muscle-invasive bladder cancer with fibroblast growth factor receptor (FGFR) alterations
Phase 2 data for ERLEADA® (apalutamide) plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localized prostate cancer show 100% biochemical free recurrence rate more than two years post-surgery
Study highlights opportunity for treatment intensification in this population since approximately 50% of patients with high-risk localized prostate cancer (HRLPC) experience disease recurrence within two years of surgery
TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non–muscle-invasive bladder cancer
New data from Phase 2b SunRISe-1 study show rapid achievement of complete response (CR) with 98% achieving a CR within 12 weeks TAR-200 provides durable CRs in patients with Bacillus Calmette-Guérin (BCG)–unresponsive high-risk non–muscle-invasive bladder cancer (NMIBC) with carcinoma in situ – a disease area with limited treatment options for patients
